3-(Boc-氨基)吡啶-2-甲酸 | 569687-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(Boc-氨基)吡啶-2-甲酸
• 中文别名: 3-(BOC-氨基)-2-甲酸吡啶
• 英文名称: 3-tert-butoxycarbonylaminopyridine-2-carboxylic acid
• 英文别名: 3-(N-Boc-amino)-pyridine-2-carboxylic acid；3-((tert-Butoxycarbonyl)amino)picolinic acid；3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-2-carboxylic acid
• CAS: 569687-82-7
• 化学式: C₁₁H₁₄N₂O₄
• 分子量: 238.243
• InChiKey: SEMXBDMLULHKBL-UHFFFAOYSA-N

物化性质

• 熔点：
  154 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• 沸点：
  348.4±27.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(Boc-氨基)吡啶-2-甲酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 3-Amino-pyridine-2-carboxylic acid thiazol-2-ylamide
  参考文献：
  名称：

  Discovery and Structural Modification of Inhibitors of Methionine Aminopeptidases from Escherichia coli and Saccharomyces cerevisiae

  摘要：

  A series of pyridine-2-carboxylic acid derivatives were synthesized according to the leads from the screening, and potent inhibitors have been obtained by structural modification. They have shown submicromolar inhibition of the enzymes (for example, for 9n, IC50 = 130 nM for EcMetAP1 and IC50 = 380 nM for ScMetAP1). They represent small-molecule MetAP inhibitors with novel structures different from alkylating fumagillin derivatives and peptidic bestatin-based MetAP inhibitor.

  DOI：

  10.1021/jm0300532
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 3-氨基吡啶-2-羧酸 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以49%的产率得到3-(Boc-氨基)吡啶-2-甲酸
  参考文献：
  名称：

  Discovery and Structural Modification of Inhibitors of Methionine Aminopeptidases from Escherichia coli and Saccharomyces cerevisiae

  摘要：

  A series of pyridine-2-carboxylic acid derivatives were synthesized according to the leads from the screening, and potent inhibitors have been obtained by structural modification. They have shown submicromolar inhibition of the enzymes (for example, for 9n, IC50 = 130 nM for EcMetAP1 and IC50 = 380 nM for ScMetAP1). They represent small-molecule MetAP inhibitors with novel structures different from alkylating fumagillin derivatives and peptidic bestatin-based MetAP inhibitor.

  DOI：

  10.1021/jm0300532

文献信息

• A convenient synthesis of new pyrido[3,2-e][1,4]diazepine-2,5-diones and pyrido[2,3-e][1,4]diazepine-2,5-diones
  作者：Abderrahman El Bouakher、Hélène Laborie、Mina Aadil、Ahmed El Hakmaoui、Said Lazar、Mohamed Akssira、Marie-Claude Viaud-Massuard

  DOI：10.1016/j.tetlet.2011.07.098

  日期：2011.9

  4]diazepine-2,5-diones 9, is reported using the condensation of α-amino acid methyl ester derivatives with 1H-pyrido[3,2-d][1,3]oxazine-2,4-dione and 1H-pyrido[2,3-d][1,3]oxazine-2,4-dione. Compounds 8 and 9 were also synthesized by peptide coupling of α-amino acid methyl ester derivatives with β-amino acids (2 or 3) followed by the cyclisation in tetrahydrofuran with sodium hydride (NaH).

  一系列吡啶并[3,2- e ] [1,4]-二氮杂-2,5-二酮8和吡啶并[2,3- e ] [1,4]二氮杂-2,5-二酮的便捷合成9，是使用α-氨基酸甲基酯衍生物的缩合用1报道ħ -吡啶并[3,2- d ] [1,3]恶嗪-2,4-二酮和1- ħ -吡啶并[2,3- d ] [1,3]恶嗪-2,4-二酮。还通过将α-氨基酸甲酯衍生物与β-氨基酸（2或3）进行肽偶联来合成化合物8和9，然后在四氢呋喃中用氢化钠（NaH）环化。
• KR20240105730A
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery and Structural Modification of Inhibitors of Methionine Aminopeptidases from <i>Escherichia </i><i>c</i><i>oli </i>and <i>Saccharomyces </i><i>c</i><i>erevisiae</i>
  作者：Qun-Li Luo、Jing-Ya Li、Zhi-Ying Liu、Ling-Ling Chen、Jia Li、Zhen Qian、Qiang Shen、Yu Li、Gerald H. Lushington、Qi-Zhuang Ye、Fa-Jun Nan

  DOI：10.1021/jm0300532

  日期：2003.6.1

  A series of pyridine-2-carboxylic acid derivatives were synthesized according to the leads from the screening, and potent inhibitors have been obtained by structural modification. They have shown submicromolar inhibition of the enzymes (for example, for 9n, IC50 = 130 nM for EcMetAP1 and IC50 = 380 nM for ScMetAP1). They represent small-molecule MetAP inhibitors with novel structures different from alkylating fumagillin derivatives and peptidic bestatin-based MetAP inhibitor.